**Checklist for Reporting Human Islet Preparations Used in Research**

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>.

|  |  |
| --- | --- |
|  | |
| **Manuscript DOI:** https://doi.org/10.2337/**[DB19-0525.R1]** | |
| **Title: Low Dose IL-2 Combined with Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Tregs and Prolonged Human Islet-allograft Survival in Humanized Mice** | |
| **Author list:** Min Hu, Wayne J Hawthorne, Leigh Nicholson, Heather Burns, Yi Wen Qian, David Liuwantara, Elvira Jimenez Vera, Yi Vee Chew, Lindy Williams, Shounan Yi, Karen Keung,Debbie Watson, Natasha Rogers, Stephen I Alexander and Philip J O’Connell | |
| **Corresponding author:** Min Hu and Philip J O’Connell | **Email address:min.hu@sydney.edu.au and philip.oconnell@sydney.edu.au** |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Islet preparation** | **9** | **10** | **11** | **12** | **13** | **14** | **15** | **16a** |
| **MANDATORY INFORMATION** | | | | | | | | |
| Unique identifier | V1586 | N1852 | S0949 | D14-0220 | D15-0075 | D16-0121 | D16-0204 | D16-0247 |
| Donor age (years) | 45 | 47 | 56 | 56 | 51 | 40 | 51 | 56 |
| Donor sex (M/F) | M | M | F | F | M | F | F | F |
| Donor BMI (kg/m2) | 22.59 | 23.52 | 36.05 | 29.39 | 26.89 | 33.66 | 31.23 | 29.03 |
| Donor HbA1c or other measure of blood glucose control | (BSL)6.3 mmol/L | 6.2 | 6.7 | 7.5 | 8.6 | N/A | 8.4 | 7.1 |
| Origin/source of isletsb | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium | Australian Islet Transplant Consortium |
| Islet isolation centre | WIT | WIT | WIT | WIT | WIT | WIT | WIT | WIT |
| Donor history of diabetes? Yes/No | No | No | No | No | No | No | No | No |
| **If Yes, complete the next two lines if this information is available** | | | | | | | | |
| Diabetes duration (years) |  |  |  |  |  |  |  |  |
| Glucose-lowering therapy at time of deathc |  |  |  |  |  |  |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **RECOMMENDED INFORMATION** | | | | | | | | |
| Donor cause of death | Spontaneous SAH | ICH | SAH | ICH | Gunshot | SAH | ICH | ICH |
| Warm ischaemia time (h) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cold ischaemia time (h) | 7.45 | 1.3 | 7.43 | 7.58 | 4.98 | 4.38 | 3.8 | 8.75 |
| Estimated purity (%) | 85 | 85 | 95 | 85 | 85 | 85 | 90 | 85 |
| Estimated viability (%) | 83 | 97 | 94 | 90 | 83 | 95 | 95 | 90 |
| Total culture time (h)d | 29.5 | 6 | 6.5 | 17 | 7.5 | 29 | 15 | 27 |
| Glucose-stimulated insulin secretion or other functional measuremente | 2.68 | N/A | 1.29 | 1.51 | 1.03 | 1.07 | 3.05 | 2.7 |
| Handpicked to purity? Yes/No | No | No | No | No | No | No | No | No |
| Additional notes |  |  |  |  |  |  |  |  |

aIf you have used more than eight islet preparations, please complete additional forms as necessary

bFor example, IIDP, ECIT, Alberta IsletCore

cPlease specify the therapy/therapies

dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

ePlease specify the test and the results